C4XD vs. SAR, OBD, HEMO, OPTI, SBTX, AREC, ONC, DEST, TRX, and OBI
Should you be buying C4X Discovery stock or one of its competitors? The main competitors of C4X Discovery include Sareum (SAR), Oxford BioDynamics (OBD), Hemogenyx Pharmaceuticals (HEMO), OptiBiotix Health (OPTI), SkinBioTherapeutics (SBTX), Arecor Therapeutics (AREC), Oncimmune (ONC), Destiny Pharma (DEST), Tissue Regenix Group (TRX), and Ondine Biomedical (OBI). These companies are all part of the "biotechnology" industry.
Sareum (LON:SAR) and C4X Discovery (LON:C4XD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
Sareum currently has a consensus price target of GBX 304, indicating a potential upside of 955.56%. Given C4X Discovery's higher probable upside, analysts plainly believe Sareum is more favorable than C4X Discovery.
Sareum has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, C4X Discovery has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.
In the previous week, C4X Discovery's average media sentiment score of 0.48 beat Sareum's score of 0.00 indicating that Sareum is being referred to more favorably in the media.
C4X Discovery has higher revenue and earnings than Sareum. Sareum is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.
52.1% of C4X Discovery shares are held by institutional investors. 4.0% of Sareum shares are held by company insiders. Comparatively, 27.1% of C4X Discovery shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
C4X Discovery received 6 more outperform votes than Sareum when rated by MarketBeat users. Likewise, 77.88% of users gave C4X Discovery an outperform vote while only 66.13% of users gave Sareum an outperform vote.
C4X Discovery has a net margin of 42.81% compared to C4X Discovery's net margin of 0.00%. Sareum's return on equity of 55.38% beat C4X Discovery's return on equity.
Summary
C4X Discovery beats Sareum on 12 of the 15 factors compared between the two stocks.
Get C4X Discovery News Delivered to You Automatically
Sign up to receive the latest news and ratings for C4XD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding C4XD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
C4X Discovery Competitors List
Related Companies and Tools
